As MMPs are recognized as a therapeutic target for many cancers [2,48], our work indicates that despite the karyotypic heterogeneity among AML patients, MT1-MMP expression appears to be almost ubiquitous and suggests that targeting of MT1-MMP as part of a combinatorial approach should be investigated in designing future treatments for AML. Here, MMP14 is linked to acute myeloid leukemia.